Logically speaking handgrip should decrease HOCM murmur. The murmur in HOCM stems from outlet obstruction. Increased afterload-->dealayed/decreased emptying of LV-> 'smoother' LV function --> decreased murmur.
SUTM is wrong. IHSS and MVP both decrease in intensity with sustained handgrip -- because it increases afterload and causes increased LV size - which would reduce the size of the defect in both MVP and HOCM
Few errors to contribute (found a lot in here, and most of them are marked, but can't find most of them):
pg. 5 midway down, typo: should read "interferon" not "interreron"
pg 126 - first line treatment for osteoarthritis is Tylenol (acetaminophen) not NSAIDs - remember OA is not a true inflammatory condition - thus can be treated with Tylenol. The side effect profile of NSAIDs is much worse and shouldn't be used when not needed.
pg 147 - not an egregious error, but more a point of contention - under diagnostic testing - a decreased haptoglobin level is definitely found in intravascular hemolysis - but is variable and maybe normal in extravascular - what i read about this was kinda conflicting, but just something to keep in mind.
pg 149 - in the red text when referrring to the treatment of sickle cell: Hydroxyurea is indicated in any patient with greater than or equal to 3 crises a year
(i might be wrong on this one - i'm pretty sure I am - seen some places say 50, some say 55, some say 45+, some even say 40+) pg 172: The very bottom on the answer explanation - You should do an upper endoscopy on any patient over 40
(see above) pg 173: On Peptic Ulcer disease - last sentence - you should scope any patient over 40, not 45
pg 197 - Ursodeoxycholic acid is not used in the treatment of PSC - From Epocrates: "Although UDCA typically improves liver tests... a positive effect of UDCA on PSC has been difficult to demonstrate... more recent evidence suggests that high-dose UDCA may fail to show an improvement in survival. Of further relevance, this trial was terminated early because of concern over adverse effects (more patients in the treated group reached one of the pre-established clinical end points: hepatic decompensation, cholangiocarcinoma, liver transplantation, or death). [45] Therefore, UDCA at any dose cannot currently be recommended for the treatment of PSC"
--- instead treatment should be Cholestryamine for pruritis and Liver transplant as definitive therapy
pg 209 - Ca channel blockers are considered first line in the preventative therapy of cluster headaches
pg. 254 - "Lumpectomy with radiation treatment of the site at the breast is equal to modified radical mastectomy in tumors up to 4 cm." - if greater than or equal to 4 cm, you need to perform radical mastectomy
pg 256: At the table on the top for the 3rd colum with "Three family members, etc." the bottom of the column should ready: "Colonscopy at age 25, then every 1-2 years"
pg 298 - Under managment of acute cholecystitis - #2 should read "These are followed by EARLY cholecystectomy (after 24-48 hours)" --- this has been shown to be best management strategy.
pg. 315 - The treatment for Acute epididymitis for males < 35 should have Ceftriaxone as the drug listed not cipro (and doxycycline is also spelled wrong).
pg. 380 - in the blue box - in the Diagnostic significance column - it has Trisomy 21 listed 2 times. The second trisomy 21 should be Trisomy 18 (Edwards syndrome) --- while you're at it, add in that Inhibin A is increased for T21 and decreased in T18
pg. 382 - the 2nd bullet point at the top - the sugar values are backwards: it should be 180 mg/dL at 1 hour and 140 mg/dL at 3 hours (the 2 hour value is correct)
page 390, the answer should be triple therapy. The most effective at reducing transmission is triple therapy. One drug can not be better than 3 drugs at reducing transmission particularly when there is an increasing prevalence of Zidovudine resistant HIV.